References: Akha AA, Berger SB, Miller RA. Enhancement of CD8 T-cell function through modifying surface glycoproteins in young and old mice.Immunology. 2006 Oct;119(2):187-94. (16G6, Intracellular Flow, PubMed)
Kapp JA, Honjo K, Kapp LM, Xu XY, Cozier A, Bucy RP. TCR transgenic CD8+ T cells activated in the presence of TGFbeta express FoxP3 and mediate linked suppression of primary immune responses and cardiac allograft rejection. Int Immunol. 2006; 1-14. (16G6, IC flow, PubMed)
Kilinc MO, Aulakh KS, Nair RE, Jones SA, Alard P, Kosiewicz MM, Egilmez NK. Reversing Tumor Immune Suppression with Intratumoral IL-12: Activation of Tumor-Associated T Effector/Memory Cells, Induction of T Suppressor Apoptosis, and Infiltration of CD8+ T Effectors. J Immunol. 2006 Nov 15;177(10):6962-73 (16G6, IC Flow, PubMed)
Smyth, M., et al. 1995. Granzymes: exogenous proteinases that induce target cell apoptosis. Immunol Today. 16: 202-206.
Shafer-Weaver, K., et al. 2003. The Granzyme B ELISPOT assay: an alternative to the 51Cr-release assay for monitoring cell-mediated cytotoxicity. J. Translational Med. 1: 14.
Rininsland, F., et al. 2000. Granzyme B ELISPOT assay for ex vivo measurements of T cell immunity. J Immunol Meth. 240:143-155.